|
US5658920A
(en)
|
1991-01-16 |
1997-08-19 |
Daiichi Pharmaceutical Co., Ltd. |
Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
|
|
US6504029B1
(en)
|
1995-04-10 |
2003-01-07 |
Daiichi Pharmaceutical Co., Ltd. |
Condensed-hexacyclic compounds and a process therefor
|
|
DK0841924T3
(da)
|
1995-08-02 |
2003-02-10 |
Univ Newcastle Ventures Ltd |
Benzimidazolforbindelser
|
|
WO1997041124A1
(en)
|
1996-04-26 |
1997-11-06 |
Daiichi Pharmaceutical Co., Ltd. |
Process for the preparation of tetrahydro-indolizines
|
|
TW409058B
(en)
|
1996-06-06 |
2000-10-21 |
Daiichi Seiyaku Co |
Method for preparation of a drug complex
|
|
TW527183B
(en)
|
1996-06-06 |
2003-04-11 |
Daiichi Seiyaku Co |
Drug complex
|
|
IN189180B
(enExample)
|
1997-07-09 |
2003-01-04 |
Chong Kun Dang Corp |
|
|
MY132496A
(en)
|
1998-05-11 |
2007-10-31 |
Vertex Pharma |
Inhibitors of p38
|
|
WO1999061061A1
(fr)
|
1998-05-22 |
1999-12-02 |
Daiichi Pharmaceutical Co., Ltd. |
Composites medicamenteux
|
|
MXPA01004239A
(es)
|
1998-10-30 |
2002-06-04 |
Daiichi Seiyaku Co |
Compuesto dds y metodo para la medicion del mismo.
|
|
TR200101239T2
(tr)
|
1998-11-03 |
2001-11-21 |
Basf Aktiengesellschaft |
İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
|
|
EP1140936B1
(en)
|
1999-01-11 |
2004-03-17 |
Agouron Pharmaceuticals, Inc. |
Tricyclic inhibitors of poly(adp-ribose) polymerases
|
|
DE19920936A1
(de)
|
1999-05-07 |
2000-11-09 |
Basf Ag |
Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
|
|
ECSP003637A
(es)
|
1999-08-31 |
2002-03-25 |
Agouron Pharma |
Inhibidores triciclicos de poli (adp-ribosa) polimerasas
|
|
US6699876B2
(en)
|
1999-11-18 |
2004-03-02 |
Les Laboratoires Servier |
Camptothecin analogue compounds
|
|
WO2001041534A2
(en)
|
1999-12-13 |
2001-06-14 |
Eli Lilly And Company |
Pseudomycin phosphate prodrugs
|
|
AU4583601A
(en)
|
2000-03-15 |
2001-09-24 |
Du Pont Pharm Co |
Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
|
|
AU2001271037A1
(en)
|
2000-07-13 |
2002-01-30 |
Daiichi Pharmaceutical Co., Ltd. |
Pharmaceutical compositions containing dds compounds
|
|
US7151102B2
(en)
|
2000-10-30 |
2006-12-19 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US7771727B2
(en)
|
2002-03-01 |
2010-08-10 |
The Administrators Of The Tulane Educational Fund |
Conjugates of therapeutic or cytotoxic agents and biologically active peptides
|
|
GEP20074230B
(en)
|
2002-03-20 |
2007-11-12 |
Bristol Myers Squibb Co |
Phosphate prodrugs of fluorooxindoles
|
|
DE60335359D1
(de)
|
2002-04-30 |
2011-01-27 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
JP2006522088A
(ja)
|
2003-03-31 |
2006-09-28 |
ファイザー・インク |
ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
KR20060080535A
(ko)
|
2003-05-14 |
2006-07-10 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
EP1651162B1
(en)
|
2003-05-20 |
2015-10-21 |
ImmunoGen, Inc. |
Improved cytotoxic agents comprising new maytansinoids
|
|
GB0317466D0
(en)
|
2003-07-25 |
2003-08-27 |
Univ Sheffield |
Use
|
|
MXPA06000993A
(es)
|
2003-07-25 |
2006-08-31 |
Cancer Rec Tech Ltd |
Inhbidores triciclicos de parp.
|
|
SG150548A1
(en)
|
2003-12-01 |
2009-03-30 |
Kudos Pharm Ltd |
Dna damage repair inhibitors for treatment of cancer
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
BRPI0510909A2
(pt)
*
|
2004-05-19 |
2008-12-16 |
Medarex Inc |
composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
|
|
CN101098854B
(zh)
*
|
2004-07-23 |
2012-12-05 |
恩多塞特公司 |
二价连接体及其轭合物
|
|
CA2581025C
(en)
|
2004-09-22 |
2011-06-07 |
Pfizer Inc. |
Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
|
JP2008513435A
(ja)
|
2004-09-22 |
2008-05-01 |
ファイザー・インク |
ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
|
|
CA2580833C
(en)
|
2004-09-22 |
2010-12-21 |
Pfizer, Inc. |
Method of preparing poly(adp-ribose) polymerases inhibitors
|
|
KR101281501B1
(ko)
|
2004-12-09 |
2013-07-15 |
얀센 바이오테크 인코포레이티드 |
항인테그린 면역 컨쥬게이트, 방법 및 용도
|
|
WO2006078816A2
(en)
|
2005-01-18 |
2006-07-27 |
The Board Of Governors For Higher Education |
Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
|
|
US7301019B2
(en)
|
2005-01-21 |
2007-11-27 |
Immunogen, Inc. |
Method for the preparation of maytansinoid esters
|
|
US7811572B2
(en)
|
2005-08-24 |
2010-10-12 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
AU2006213662B2
(en)
|
2005-02-11 |
2010-08-05 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
EA200702239A1
(ru)
|
2005-04-15 |
2008-10-30 |
Иммьюноджен, Инк. |
Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
|
|
CN101316834A
(zh)
|
2005-09-29 |
2008-12-03 |
艾博特公司 |
在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
|
|
WO2007056550A2
(en)
|
2005-11-08 |
2007-05-18 |
Immunogen, Inc. |
Processes for preparation of maytansinol
|
|
SI2338487T1
(sl)
|
2006-01-17 |
2014-01-31 |
Abbott Laboratories |
Kombinacijska terapija z inhibitorji PARP
|
|
WO2007131133A2
(en)
|
2006-05-04 |
2007-11-15 |
Genentech, Inc. |
Methods and compositions relating to zpa polypeptides
|
|
UY30639A1
(es)
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
|
WO2008114114A2
(en)
|
2007-03-16 |
2008-09-25 |
Pfizer Products Inc. |
Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
|
|
BRPI0812970A2
(pt)
*
|
2007-06-25 |
2019-09-24 |
Endocyte Inc |
conjugados contendo espaçadores hidrofílicos
|
|
US8067613B2
(en)
|
2007-07-16 |
2011-11-29 |
Abbott Laboratories |
Benzimidazole poly(ADP ribose)polymerase inhibitors
|
|
DK2187965T3
(da)
*
|
2007-08-17 |
2020-01-20 |
Purdue Research Foundation |
Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
|
|
UA108598C2
(xx)
|
2008-04-30 |
2015-05-25 |
|
Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
|
|
PE20100083A1
(es)
|
2008-06-05 |
2010-02-17 |
Janssen Pharmaceutica Nv |
Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
|
|
JP5784592B2
(ja)
|
2009-06-03 |
2015-09-24 |
イミュノジェン・インコーポレーテッド |
抱合方法
|
|
US9353140B2
(en)
|
2009-11-25 |
2016-05-31 |
Academia Sinica |
BQC-G, a tumor-selective anti-cancer prodrug
|
|
ES2607806T5
(es)
|
2010-02-12 |
2024-10-07 |
Pfizer |
Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
|
|
CA2790577A1
(en)
*
|
2010-02-25 |
2011-09-01 |
Purdue Research Foundation |
Psma binding ligand-linker conjugates and methods for using
|
|
AP2012006535A0
(en)
|
2010-03-31 |
2012-10-31 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorous containing actives
|
|
WO2011140393A1
(en)
|
2010-05-05 |
2011-11-10 |
Prolynx Llc |
Controlled release from macromolecular conjugates
|
|
CA3032186C
(en)
|
2010-07-13 |
2022-04-26 |
Council on Postsecondary Education, State of Rhode Island and Providence Plantations |
Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
|
|
US8846081B2
(en)
|
2010-08-13 |
2014-09-30 |
Rhode Island Board Of Governors For Higher Education |
Liposome compositions and methods of use thereof
|
|
US9090629B2
(en)
|
2010-11-03 |
2015-07-28 |
Immunogen, Inc. |
Cytotoxic agents comprising new ansamitocin derivatives
|
|
WO2012135517A2
(en)
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
EA033468B1
(ru)
|
2011-03-29 |
2019-10-31 |
Immunogen Inc |
Способы получения конъюгата "антитело-майтансиноид"
|
|
JP6104257B2
(ja)
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピンおよびそのコンジュゲート
|
|
US10195288B2
(en)
|
2012-10-11 |
2019-02-05 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
US9180203B2
(en)
*
|
2012-10-23 |
2015-11-10 |
The Johns Hopkins University |
Self-assembling drug amphiphiles and methods for synthesis and use
|
|
WO2014093343A2
(en)
|
2012-12-10 |
2014-06-19 |
Massachusetts Institute Of Technology |
Multistage nanoparticle drug delivery system for the treatment of solid tumors
|
|
EP2927227A4
(en)
|
2013-01-03 |
2015-12-30 |
Celltrion Inc |
ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
|
|
HK1219422A1
(zh)
|
2013-02-28 |
2017-04-07 |
Immunogen, Inc. |
包含细胞结合剂及细胞毒素剂的轭合物
|
|
CN105813653B
(zh)
|
2013-12-19 |
2020-06-26 |
西雅图基因公司 |
与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
|
|
JP6663350B2
(ja)
|
2014-01-16 |
2020-03-11 |
クロヴィス・オンコロジー，インコーポレーテッド |
ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
JP2017114763A
(ja)
|
2014-03-26 |
2017-06-29 |
第一三共株式会社 |
抗ｃｄ９８抗体−薬物コンジュゲート
|
|
TWI871999B
(zh)
|
2014-04-10 |
2025-02-01 |
日商第一三共股份有限公司 |
抗her3抗體-藥物結合物
|
|
US11185594B2
(en)
|
2014-04-10 |
2021-11-30 |
Daiichi Sankyo Company, Limited |
(Anti-HER2 antibody)-drug conjugate
|
|
EP3164420A4
(en)
|
2014-06-30 |
2018-05-23 |
Tarveda Therapeutics, Inc. |
Targeted conjugates and particles and formulations thereof
|
|
KR20170043597A
(ko)
|
2014-08-22 |
2017-04-21 |
클로비스 온콜로지 인코포레이티드 |
루카파립의 고 용량 강도 정제
|
|
CA2944085C
(en)
|
2014-09-16 |
2018-04-10 |
Ease Charm Limited |
Anti-egfr antibody and uses of same
|
|
PL3204018T3
(pl)
|
2014-10-07 |
2022-01-03 |
Immunomedics, Inc. |
Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
|
|
CA2966932A1
(en)
|
2014-11-19 |
2016-05-26 |
Immunogen, Inc. |
Process for preparing cell-binding agent-cytotoxic agent conjugates
|
|
JO3705B1
(ar)
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
KR102407261B1
(ko)
|
2015-02-27 |
2022-07-06 |
서울대학교산학협력단 |
나노 항암제형 및 그 제조 방법
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
CN108473538B
(zh)
|
2015-10-28 |
2022-01-28 |
塔弗达治疗有限公司 |
Sstr靶向缀合物及其颗粒和制剂
|
|
CA3003283A1
(en)
|
2015-11-24 |
2017-06-01 |
Theravance Biopharma R&D Ip, Llc |
Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
|
|
KR102498258B1
(ko)
|
2016-01-20 |
2023-02-10 |
삼성디스플레이 주식회사 |
표시 장치
|
|
US20170267727A1
(en)
|
2016-03-04 |
2017-09-21 |
Lehigh University |
Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
|
|
WO2017156191A1
(en)
|
2016-03-08 |
2017-09-14 |
Los Gatos Pharmaceuticals, Inc. |
Composite nanoparticles and uses thereof
|
|
WO2017180834A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Tarveda Therapeutics, Inc. |
Neurotensin receptor binding conjugates and formulations thereof
|
|
GB201608885D0
(en)
|
2016-05-20 |
2016-07-06 |
Univ Birmingham |
Treatment
|
|
WO2017210608A1
(en)
|
2016-06-02 |
2017-12-07 |
Yale University |
Compositions and methods for targeting and treating homologous recombination-deficient tumors
|
|
WO2018023098A1
(en)
|
2016-07-29 |
2018-02-01 |
Memorial Sloan Kettering Cancer Center |
Radiolabeled ligands for targeted pet/spect imaging and methods of their use
|
|
PH12019500306B1
(en)
|
2016-08-16 |
2024-02-21 |
Aist |
Malignant tumor target peptide
|
|
JP7181875B2
(ja)
*
|
2016-09-22 |
2022-12-01 |
ユニバーシティー オブ ロード アイランド ボード オブ トラスティーズ |
ｐＨトリガーポリペプチドにコンジュゲートしたフルオロフォアを含む蛍光化合物
|
|
EP3546448B1
(en)
|
2016-11-25 |
2022-04-06 |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
|
|
US10040831B2
(en)
|
2016-12-19 |
2018-08-07 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
CA3066384A1
(en)
|
2017-06-09 |
2018-12-13 |
Rhode Island Council On Postsecondary Education |
Linked and other ph-triggered compounds
|
|
SG11202001514XA
(en)
|
2017-08-31 |
2020-03-30 |
Daiichi Sankyo Co Ltd |
Novel method for producing antibody-drug conjugate
|
|
AU2019205325A1
(en)
|
2018-01-05 |
2020-08-13 |
Cybrexa 1, Inc. |
Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
|
|
JP2021510702A
(ja)
|
2018-01-12 |
2021-04-30 |
プロリンクス エルエルシー |
相乗的がん治療
|
|
EP3794042B1
(en)
|
2018-05-18 |
2024-03-27 |
Daiichi Sankyo Co., Ltd. |
Anti-muc1- exatecan antibody-drug conjugate
|
|
TWI920652B
(zh)
|
2018-06-07 |
2026-04-01 |
美商思進公司 |
喜樹鹼結合物
|
|
CN109232719B
(zh)
|
2018-09-21 |
2021-06-29 |
中国科学院理化技术研究所 |
一种pH响应的抗菌肽及其制备方法和应用
|
|
EP3917528A4
(en)
|
2019-01-28 |
2022-12-28 |
University of Rhode Island Board of Trustees |
TARGETED DELIVERY OF POTENT CYTOTOXIC COMPOUNDS WITH PHLIP®
|
|
KR20240104214A
(ko)
|
2019-03-29 |
2024-07-04 |
메디뮨 리미티드 |
화합물 및 이의 접합체
|
|
BR112022000297A2
(pt)
|
2019-07-10 |
2022-03-15 |
Cybrexa 3 Inc |
Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
|
|
MX2022000449A
(es)
|
2019-07-10 |
2022-04-25 |
Cybrexa 2 Inc |
Conjugados peptídicos de citotoxinas como terapéuticos.
|
|
JP2024503380A
(ja)
|
2021-01-08 |
2024-01-25 |
サイブレクサ ２，インコーポレイテッド |
コンジュゲート連結部分を調製するための方法
|
|
JP2024516825A
(ja)
|
2021-04-29 |
2024-04-17 |
サイブレクサ ２，インコーポレイテッド |
トポイソメラーゼｉ阻害剤のペプチドコンジュゲートの投与レジメン
|
|
AU2022390891A1
(en)
|
2021-11-17 |
2024-06-06 |
Cybrexa 4, Inc. |
Peptide conjugates of peptidic tubulin inhibitors as therapeutics
|